Thank you to our sponsors!
2
We Want to Hear From You!
Feedback Survey At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey. This will also be emailed to you shortly after the workshop. Please take a moment to complete this survey.
Video Replay
A replay of the webinar will be made available on our website early next week. You can find it under the Publications and Broadcasts Tab, and then under IMF Broadcasts. A replay link will be directly emailed to all who registered for this webinar.
Top Myeloma Research Presented at ASH 2023
1
Brian G.M. Durie, MD January 4, 2023
IMF Mission ASH 2023 ➢ Total Attendance: 32,000 (28,000 in-person; 4,000 virtual) ➢ Total Number of Abstracts: 7,000 ➢ Myeloma Abstracts: over 1,000 - Oral Presentations: 136 + LBA & Plenary - Posters: About 850
6
Myeloma Support Group Leader Voices at ASH 2023 IMF Mission Read the Blogs: Myeloma Support Group Leader Voices at ASH 2023
7
Myeloma Support Group Leader Voices at ASH 2023 IMF Mission
The ASH 2023 Experience with
Michael Tuohy, Patient (In-person)
8
Jessie Daw, Patient (Virtual)
IMFMRD Mission What is the i2TEAMM?
The MRD i2TEAMM is an International Independent Team for the Endpoint Approval of MRD in Myeloma
9
IMF Mission MRD i2TEAMM Update ➢ ACTIVE engagement with FDA for 2024 ➢ Optimistic MRD at 10-5 or better will be approved AS AN EARLY ENDPOINT FOR ACCELERATED DRUG APPROVALS ➢ Full approval still requires PFS benefit ➢ REAL WORLD USE OF MRD under review
10
IMF Global Technology Platform Imaging
Iceland Early disease
Family Studies
Full sequencing
Germany
Retrospective studies
Mayo
Central Platform
France
Cure Trial
Spain
CLIA lab NGF & MASS SPEC
Immune monitoring
Pipeline trials Immune Therapy Database
7
Asian Trials Network
Blood monitoring
Centralized NGF/risk assessment
Singapore Virtual Biobank
Single cell resistance analyses Trials Pending Latin America Network
Blood DNA mutational analyses Clinical trial assessment
Australia
IMFQ&A Mission
12
IMF Mission Top ASH Abstracts
➢ 4-Drug Combos in Frontline ➢ - Daratumumab + Velcade-Revlimid-Dexamethasone (VRd)…PERSEUS Trial European Myeloma Network (EMN)… Late Breaking Abstract (LBA) - Isatuximab + Carfilzomib-Lenalidomide-Dexamethasone (KRd)…IsKia Trial (EMN 24)… Plenary
13
IMF Mission Fibrinogen and Ferritin How are Fibrinogen and Ferritin involved in ICANS and and CRS? ▪ The study concluded that higher fibrinogen and ferritin values at baseline were associated with inferior overall survival after CAR T-cell therapy. ▪ Higher baseline absolute lymphocyte counts were linked to a higher risk of ICANS and higher grade of ICANS, an important toxicity to consider for patients receiving CAR T. ▪ Higher ferritin equated to shorter progression-free survival. CAR T-cell therapy is a highly effective treatment option, but outcomes and duration of response can vary widely, so if we can use widely available tests to help determine outcomes, this could possibly impact treatment decisions. ▪ Abstract 92: Inflammatory Biomarkers and Outcomes in Multiple Myeloma Patients after CAR T-Cell Therapy
14
IMFNew Mission Two Key Projects
VIRTUAL TISSUE BANK
15
IMMUNE THERAPIES REGISTRY
Confidential - Not for Distribution
IMF Mission Outpatient CAR T and Bispecifics Can we safely manage CAR T and bispecifics on an Outpatient Basis? Robin Tuohy
Care Partner and IMF Vice President – Support Groups
16
Interview with Linda Huguelet on her CAR T treatment
IMF Mission PERSEUS Trial
17
IMF Mission PERSEUS Trial
18
IMF Mission PERSEUS Trial
19
IMF Mission PERSEUS Trial
20
IMF Mission IsKia Trial
21
IMF Mission IsKia Trial
22
IMF Mission IsKia Trial
23
IMF Mission FRONTLINE 2024
❖ 4 Drugs can be approved ❖ HOWEVER …will they be reimbursed? … are added toxicity/side effects worth it?
24
IMFQ&A Mission
25
IMF Mission ASH 2023
STATUS OF MRD TESTING
26
IMF Mission ASH 2023- STATUS OF MRD TESTING
27
IMF Mission ASH 2023- STATUS OF MRD TESTING
28
IMF Mission ASH 2023- STATUS OF MRD TESTING
29
IMF Mission ASH 2023- STATUS OF MRD TESTING
30
IMFQ&A Mission
31
IMF Mission iStopMM Project
32
IMF Mission iStopMM Project
33
IMF Mission iStopMM Project
34
iStopMM Project: The Flow Chart IMFRandomization Mission
35
IMF Mission iStopMM Project
36
IMF Mission iStopMM Project
37
IMFQ&A Mission
38
Other ASH 2023 Takeaways ➢ REAL WORLD DATASETS ➢ EMPHASIS on Equity & Access and outcomes ➢ New IMMUNE THERAPIES: Biology/outcomes ➢ HR SMM: Criteria, biology, therapies ➢ AND MANY CLINICAL PEARLS
39
IMF Mission Clinical Pearls ➢ Taper DEX ➢ CAR T Access Improved/Safety Issues? ➢ Other CAR T: FasT CAR T/Dd BCMA/GPRC5D ➢ Teclistamab for HR SMM (IMMUNO Prism) vs R/KRd/Dara KRd/other ➢ Trispecifics: JNJ 5322 and HPN217 ➢ Immune therapy dose/duration questions ➢ SIDE EFFECTS: Infections/Skin, Nails, and Taste (dysgeusia) in addition to CRS/ICANS
40
IMF Mission Final Comments
FINAL COMMENTS
41
ASH 2024
42
will be held in San Diego again!
43
We Want to Hear From You!
Feedback Survey At the close of the meeting a feedback survey will pop up. Click “continue” to complete the survey. This will also be emailed to you shortly after the workshop. Please take a moment to complete this survey.
Video Replay
A replay of the webinar will be made available on our website early next week. You can find it under the Publications and Broadcasts Tab, and then under IMF Broadcasts. A replay link will be directly emailed to all who registered for this webinar.
Thank you to our sponsors!
46